Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · IEX Real-Time Price · USD
4.59
-0.12 (-2.55%)
Nov 28, 2023, 4:00 PM EST - Market closed
Company Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States.
Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema.
The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021.
Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Astria Therapeutics, Inc.
| Country | United States |
| Founded | 2008 |
| IPO Date | Jun 25, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Ms. Jill C. Milne Ph.D. |
Contact Details
Address: 75 State Street, Suite 1400 Boston, Massachusetts 02109 United States | |
| Phone | 617-349-1971 |
| Website | astriatx.com |
Stock Details
| Ticker Symbol | ATXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001454789 |
| CUSIP Number | 04635X102 |
| ISIN Number | US04635X1028 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jill C. Milne Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Noah Clauser CPA | Chief Financial Officer |
| Dr. Andrew J. Nichols Ph.D. | Chief Scientific Officer |
| Benjamin S. Harshbarger J.D. | Chief Legal Officer |
| Keri McGrail | Senior Vice President of Human Resources |
| Andrea L. Matthews | Senior Vice President of Corporate Affairs |
| Andrew A. Komjathy | Chief Commercial Officer |
| Dr. Anthony Christopher Stevens M.D. | Interim Chief Medical Officer |
| Dr. Christopher J. Morabito M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 13, 2023 | 8-K | Current Report |
| Oct 18, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 12, 2023 | 8-K | Current Report |
| Oct 12, 2023 | 424B5 | Filing |
| Oct 12, 2023 | 8-K | Current Report |
| Oct 12, 2023 | FWP | Free Writing Prospectus |
| Oct 11, 2023 | 8-K | Current Report |
| Aug 7, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 7, 2023 | 10-Q | Quarterly Report |